Claims for Patent: 9,718,880

✉ Email this page to a colleague

Summary for Patent: 9,718,880

Title:	Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
Abstract:	Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.
Inventor(s):	Bell; Leonard (Woodbridge, CT), Rother; Russell P. (Oklahoma City, OK), Evans; Mark J. (Radnor, PA)
Assignee:	Alexion Pharmaceuticals, Inc. (New Haven, CT)
Application Number:	15/148,839
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,718,880
Patent Claims:	1. A pharmaceutical composition for use in treating a patient afflicted with paroxysmal nocturnal hemoglobinuria (PNH), wherein the composition is a sterile, preservative free, 300 mg single-use dosage form comprising 30 ml of a 10 mg/ml antibody solution, wherein the antibody comprises a heavy chain consisting of SEQ ID NO: 2 and a light chain consisting of SEQ ID NO: 4. 2. A pharmaceutical composition comprising an anti-C5 antibody, wherein the anti-C5 antibody comprises a heavy chain consisting of SEQ ID NO: 2 and a light chain consisting of SEQ ID NO: 4. 3. The pharmaceutical composition of claim 2, wherein the pharmaceutical composition is a sterile, preservative free 300 mg single-use dosage form comprising 30 ml of a 10 mg/ml anti-C5 antibody solution.

Details for Patent 9,718,880

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Alexion Pharmaceuticals, Inc.	SOLIRIS	eculizumab	Injection	125166	March 16, 2007	⤷ Sign Up	2027-03-15
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 9,718,880

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2008069889	⤷ Sign Up
World Intellectual Property Organization (WIPO)	2007106585	⤷ Sign Up
World Intellectual Property Organization (WIPO)	2005074607	⤷ Sign Up
United States of America	9732149	⤷ Sign Up
United States of America	9725504	⤷ Sign Up
United States of America	2020392216	⤷ Sign Up
United States of America	2020199211	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.